ПАЦИЕНТЫ С ТЯЖЁЛЫМИ ПОРАЖЕНИЯМИ ЛЁГКИХ НА ФОНЕ СПОНДИЛОАРТРИТА ИЛИ РЕВМАТОИДНОГО АРТРИТА: ФУНКЦИЯ ВНЕШНЕГО ДЫХАНИЯ, ВЛИЯНИЕ БАЗИСНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ

Abstract

The presence of lung involvement in patients with spondyloarthritеs or rheumatoid arthritis always causes concern with regard to the choice of disease­modifying anti­rheumatic drugs. Objective. To determine clinical and instrumental peculiarities of severe lung disorders and to assess the disease­modifying anti­rheumatic drugs (methotrexate) impact on the respiratory system in patients with spondyloarthritеs and rheumatoid arthritis in the presence of severe lung disorders. Material and methods. The research involved 172 patients with spondyloarthritеs and rheumatoid arthritis. The patients were interviewed and examined. The nature of the current medication was specified. The multispiral computer tomography of thorax was performed in order to determine the presence of lung affection. Lung function was tested by means of spirometry and body plethysmography. In order to process the data Statistica 10 software package was used. Results. Lung disorders were found in 77,5 % of patients with spondyloarthritеs and 90,0 % of patients with rheumatoid arthritis. Out of all disorders severe lung disorders were found in 48,4 % of patients with spondyloarthritеs and 70,0 % of patients with rheumatoid arthritis. The patients with severe lung disorders had dyspnea, they also showed a decrease in lung function parameters. The patients with severe lung disorders who were taking methotrexate showed higher parameters of forced vital capacity and vital capacity than the patients with similar lung disorders who were not taking methotrexate. Conclusion. Severe lung disorders in patients with spondyloarthritеs and rheumatoid arthritis can be manifested by respiratory complaints and a decrease in lung function parameters. Methotrexate shows a beneficial effect on the lung function in patients with spondyloarthritеs and rheumatoid arthritis who have severe lung disorders.